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Background: Sotalol is a commonly used antiarrhythmic drug that may alter ventricular function.
Objective: To determine the effect of sotalol on echocardiographic indices of ventricular systolic
function in dogs with ventricular arrhythmias.
Animals: Thirty-five client-owned dogs with ventricular arrhythmias.
Methods: Dogs with ventricular arrhythmias (n527) had an echocardiogram and 5-minute ECG
performed at baseline and 2-4 hours post-sotalol (2-2.5 mg/kg PO once). Eight additional dogs
underwent the same protocol but did not receive sotalol (within-day variability controls). Left ven-
tricular (LV) internal dimension at end-systole normalized to bodyweight (LVIDs_N), LV ejection
fraction (LV EF), LV shortening area, LV fractional shortening, tricuspid annular plane systolic
excursion (TAPSE), and right ventricular systolic myocardial velocity were evaluated as indices of
systolic function.
Results: All indices except TAPSE had mild decreases in systolic function post-sotalol (all
P .0007) compared with baseline but only the percent change in LVIDs_N and LV EF were signif-
icantly (P .0079) different from the percent change of the same indices in control dogs. Sinus
heart rate, ventricular premature complexes/5-minutes, and arrhythmia grade also were decreased
post-sotalol (all P .01) compared with baseline when assessed by a 5-minutes ECG. No dog expe-
rienced an adverse event post-sotalol, including dogs with systolic dysfunction or atrial
enlargement.
Conclusions and Clinical Importance: A single dose of sotalol may cause a mild decrease in LV
systolic function in dogs with ventricular arrhythmias. Sotalol appears to be well tolerated, even in
dogs with atrial enlargement or systolic dysfunction.
K E YWORD S
beta-blocker, canine, echocardiography, inotropy, tachyarrhythmia
Abbreviations: 2D, two-dimensional; DCM, dilated cardiomyopathy; LA/Ao, left atrial to aortic root ratio; LV, left ventricle/ventricular; LVAd, left ventricular area
at end-diastole; LVAs, left ventricular area at end-systole; LV FS, left ventricular fractional shortening; LVIDd, left ventricular internal dimension at end-diastole;
LVIDs, left ventricular internal dimension at end-systole; LVIDs_N, left ventricular internal dimension at end-systole normalized to bodyweight; LV SA, left
ventricular shortening area; LVVd, left ventricular volume at end-diastole; LVVs, left ventricular volume at end-systole; RV, right ventricle/ventricular; RV S’, peak
systolic RV myocardial velocity at the lateral tricuspid annulus; TAPSE_N, tricuspid annular plane systolic excursion normalized to bodyweight; VPC, ventricular
premature complex.
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1 | INTRODUCTION
Sotalol is a class III antiarrhythmic drug that combines potassium
channel-blocking properties (thereby prolonging action potential dura-
tion) with nonselective b–adrenergic receptor blocking properties.
Sotalol is a commonly used PO antiarrhythmic drug for chronic man-
agement of ventricular arrhythmias in dogs. Orally administered sotalol
also may be used to acutely terminate arrhythmias in dogs that are
hemodynamically stable because of its rapid absorption, with peak
plasma concentration likely to occur within 2–4 hours postpill.1 Sotalol
appears to be a well-tolerated and an effective treatment of ventricular
arrhythmias in Boxers with familial ventricular arrhythmias,2 and clinical
experience suggests this is also true for other breeds.
Clinicians may hesitate to use sotalol in some situations. As with all
b–adrenergic receptor antagonists, sotalol has negative inotropic proper-
ties, which raises concern over its use in dogs with systolic dysfunction
or congestive heart failure. Systolic dysfunction may be present in dogs
affected with ventricular arrhythmias secondary to, for example, arrhyth-
mogenic right ventricular (RV) cardiomyopathy, dilated cardiomyopathy
(DCM), tachycardia-induced cardiomyopathy, ischemia, or myocarditis.
However, in dogs, the negative inotropic effect of sotalol (because of b–
blockade) appears to be modest (ie, approximately one-fifth the negative
inotropic effect of propranolol).3 Also, 2 independent studies in healthy
anesthetized dogs using invasive indices of left ventricular (LV) systolic
function (1dP/dt) demonstrated that the negative inotropic effect of
sotalol is attenuated or balanced by enhanced contractility secondary to
prolonged action potential duration and hence, prolonged time for cal-
cium entry.4,5 Based on these studies, the clinical impact of sotalol
administration on systolic function in dogs with ventricular arrhythmias
may be negligible, but has not yet been investigated.
Clinical experience suggests systolic dysfunction may be a com-
mon finding in dogs with ventricular arrhythmias. Systolic dysfunction
may be secondary to primary cardiac disease or a tachyarrhythmia, as
is the case with tachycardia-induced cardiomyopathy.6 In primary
cardiomyopathies such as preclinical DCM and arrhythmogenic RV
cardiomyopathy, echocardiographic identification of LV or RV sys-
tolic dysfunction provides important diagnostic and prognostic
information.7–14 Dogs affected by these diseases are also commonly
affected by ventricular arrhythmias that may be managed with sota-
lol. Therefore, understanding the echocardiographic effects of sota-
lol on systolic function in dogs with ventricular arrhythmias could
provide clinically useful information.
The objective of our study was to determine the effect of a single
PO dose of sotalol on several echocardiographic indices of RV and LV
systolic function in dogs with ventricular arrhythmias. We hypothesized
that a single PO dose of sotalol would minimally decrease echocardio-
graphic indices of ventricular systolic function.
2 | MATERIALS AND METHODS
The Institutional Animal Care and Use Committee at the University of
California, Davis (protocol #18482) approved all procedures in our
study. Owner consent for participation in the study was obtained for
each dog before enrollment.
2.1 | Animals
Study subjects were client-owned dogs that presented to the Cardiol-
ogy Service at the University of California, Davis Veterinary Medical
Teaching Hospital for evaluation of cardiac disease or were referred for
the purpose of the study. Dogs were enrolled consecutively over a 30-
month period if they were diagnosed with a ventricular arrhythmia and
were deemed to be hemodynamically stable, weighed >10 kg (for PO
sotalol dosing purposes), and were not currently taking any antiarrhyth-
mic drugs or cardiac medications known to affect ventricular function.
Dogs were required to have a hemodynamically stable ventricular
arrhythmia, defined for the purpose of our study as a ventricular
arrhythmia for which urgent antiarrhythmic treatment was not deemed
necessary by the attending board-certified veterinary cardiologist.
Dogs were excluded from the study if they required sedation to facili-
tate echocardiography, or if they were diagnosed with congestive heart
failure.
2.2 | Study design
For the purpose of this prospective study, all dogs underwent a cardio-
vascular examination, a 6-lead ECG of 5 minutes duration, and a base-
line echocardiogram. After the echocardiogram, dogs received sotalol
2-2.5 mg/kg PO once, rounded to the nearest one-quarter of an 80 or
120 mg tablet (Sotalol hydrochloride tablets, Apotex Inc, Toronto,
Ontario, Canada; sotalol group). Dogs received a single PO dose of
sotalol for the purpose of the study and not necessarily because it was
clinically indicated (ie, the study served as a pharmacodynamic study
and not a therapeutic trial). Two-to-four hours postpill, dogs underwent
a 2nd ECG and echocardiogram. This time point was selected because
peak absorption of sotalol in dogs has been shown to occur within 2–4
hours after PO administration.1 Time from sotalol administration to the
post-sotalol echocardiogram was recorded. Dogs were monitored after
the administration of sotalol until discharged to the client, which con-
cluded the study. Sotalol was continued at the discretion of the attend-
ing clinician.
To help determine the clinical relevance of the effects of sotalol on
ventricular function and to evaluate the effects of acclimation to the
hospital environment on the studied indices of ventricular function, 8
additional dogs were recruited to serve as a within-day variability con-
trols (control group) in which the same study protocol was followed
but control dogs did not receive sotalol (ie, each dog underwent an
ECG and echocardiogram and 2–4 hours later underwent a 2nd ECG
and echocardiogram).
2.3 | Echocardiographic assessment
2.3.1 | Image acquisition
All echocardiographic studies (Philips IE33 or Philips EPIQ 7, Philips
Healthcare, Andover, Massachusetts) were performed by a board-
certified veterinary cardiologist or a cardiology resident under the
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direct supervision of a board-certified veterinary cardiologist. All echo-
cardiographic recordings were made with a simultaneous ECG. A stand-
ard echocardiographic imaging protocol was followed for each dog and
standard echocardiographic imaging planes were used and optimized
for assessment of LV and RV function. An effort was made to have the
same sonographer perform the repeat echocardiographic examination
within the same dog. Tricuspid annular plane systolic excursion (TAPSE)
and peak systolic RV myocardial velocity at the lateral tricuspid annulus
(RV S’) were acquired from left apical 4-chamber views optimized for
the RV using M-mode and pulsed wave tissue Doppler imaging,
respectively.15,16
2.3.2 | Echocardiographic measurements
Echocardiographic measurements and calculations were performed by
a single investigator at a digital off-cart workstation (JLK; Syngo
Dynamic Workplace, Version 10.0.01_HF04_Rev5 [Build 2884], Sie-
mens Medical Solutions, Malvern, Pennsylvania). This investigator was
blinded to drug status and order of the echocardiographic studies. Val-
ues for each echocardiographic variable consisted of the average of 3
measurements obtained during sinus rhythm only. To avoid post-
extrasystolic potentiation and its effects on ventricular function, meas-
urements were not obtained from cardiac cycles immediately after a
ventricular premature complex (VPC). Left ventricular internal dimen-
sion from the same cardiac cycle was measured at end-diastole (LVIDd)
and end-systole (LVIDs) at the level of the papillary muscles from the
right parasternal short axis view using M-mode echocardiography. Left
atrial-to-aortic root dimension (LA/Ao) was measured in a standard
fashion from a right parasternal short axis view using 2D echocardiog-
raphy.17 A ratio >1.5 was used to indicate left atrial enlargement. Left
ventricular internal dimension at end-systole was normalized to body
weight (LVIDs_N) using the following formula: LVIDs_N5 LVIDs (cm)
4 (body weight0.315).18 Left ventricular fractional shortening (LV FS)
was calculated as ([LVIDd2 LVIDs]/LVIDd) 3 100. From the same
short axis view and using 2D echocardiography, LV area was deter-
mined by planimetry by manually tracing the internal border of the
lumen of the LV at end-diastole (LVAd) and end-systole (LVAs) while
excluding the papillary muscles. Left ventricular shortening area (LV SA;
also known as fractional area change) was calculated as ([LVAd –
LVAs]/LVAd) 3 100. From the right parasternal long axis 4-chamber
view and left apical 4-chamber view optimized for the LV, LV volume
was estimated from 2D echocardiography using Simpson’s method of
discs as previously described19 at end-diastole (LVVd) and end-systole
(LVVs). Left ventricular ejection fraction (LV EF) was calculated as
([LVVd – LVVs]/LVVd) 3 100. For the purpose of our study, LV systolic
dysfunction was defined as a LV FS <25%.18 However, breed-specific
reference values for LVVs indexed to body surface area were utilized
to diagnose systolic dysfunction in Boxers (>50 mL/m2),20 Doberman
Pinschers (>55 mL/m2),19 and Great Danes (47 mL/m2).21 Body
weight-specific reference values for TAPSE were used to determine if
RV systolic dysfunction was present, and TAPSE was normalized to
body weight (TAPSE_N) according to the following formula: TAP-
SE_N5TASPE (cm)4 (body weight0.297).16
2.4 | Electrocardiographic assessment
All dogs had a 6-lead ECG (Philips PageWriter TC70 Cardiograph, Phi-
lips Healthcare, Andover, Massachusetts) recorded while in right lateral
recumbency. All ECGs were reviewed, assessed and measured by a sin-
gle investigator (LCV) blinded to sotalol status. Average heart rate while
in sinus rhythm and number of VPCs were quantified during the 5-
minutes ECG recording. Ventricular arrhythmia severity was graded
according to the following scale adapted from a previous study22:
05no VPCs, 15 single VPCs, 25 ventricular bigeminy or trigeminy,
35 accelerated idioventricular rhythm, 45 ventricular couplets or trip-
lets, and 55 ventricular tachycardia or R-on-T phenomenon. The high-
est grade observed was the grade assigned.
2.5 | Statistical analysis
Statistical analyses were performed using a commercial software pack-
age (Prism 7 for Mac OS X, Version 7.0c, GraphPad Software, Inc, La
Jolla, California). A power calculation based on previously published
echocardiographic reproducibility and measurement variability data in
dogs23 determined that a sample size of 22 would provide 80% power
for detecting a 20% change in echocardiographic indices of LV systolic
function. A sample size of 27 was used in the study to ensure adequate
power was achieved. Descriptive statistics were generated and normal-
ity testing with the D’Agostino-Pearson test was performed for all con-
tinuous data. Data are reported as mean (standard deviation [SD])
unless otherwise stated. Differences in paired (baseline versus post-
sotalol) data were determined by a paired t-test or a Wilcoxon
matched-pairs signed rank test (if non-normally distributed). Differen-
ces in unpaired data (control versus sotalol group) were determined by
an unpaired t-test with Welch’s correction or Mann-Whitney rank-sum
test (if non-normally distributed). Ordinal data (arrhythmia grade) was
compared with a Wilcoxon matched-pairs signed rank test. A Chi-
squared test was used to compare proportions. Within-day variability
of the echocardiographic indices in the control dogs was quantified
with the coefficient of variation ([SD 4 average] 3 100). When deter-
mining the statistical significance of the 6 echocardiographic indices of
systolic function, P values were corrected using Bonferroni’s method of
multiple comparisons. That is, a P< .05 4 6 or P< .008 denotes statis-
tical significance for these comparisons. Otherwise, P< .05 was consid-
ered statistically significant.
3 | RESULTS
A total of 35 dogs were enrolled in our study, 27 in the sotalol group
and 8 in the control group. Within the sotalol group, mean (SD) age
was 9.4 (3.4) years and body weight was 31.5 (8.8) kg with 19 (70%)
dogs being female. The sotalol group consisted of 8 Boxers, 5 each
were Doberman Pinchers and mixed breeds, and other breeds were
each represented once (Labrador Retriever, Great Dane, Saint Bernard,
Portuguese Water Spaniel, Golden Retriever, Vizsla, Weimaraner, and
English Pointer). Clinical and echocardiographic diagnoses consisted of
the following: echocardiographically unremarkable in 9 dogs,
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arrhythmogenic RV cardiomyopathy in 7 dogs, preclinical DCM in 5
dogs, myxomatous mitral valve disease in 4 dogs, and mild subaortic
stenosis and suspected myocarditis of unknown etiology (cardiac tro-
ponin I528.5 ng/mL) in 1 dog each. Mean (SD) dose of sotalol
received was 2.5 (0.2) mg/kg. Time from sotalol administration to the
post-sotalol echocardiogram was 2.9 (0.4) hours. A summary of the
baseline and post-sotalol ECG and echocardiographic ventricular sys-
tolic function data are presented in Table 1 and Figure 1. All ventricular
systolic function indices (LVIDs_N, LV FS, LV SA, LV EF, TAPSE_N, and
RV S’) documented decreased systolic function post-sotalol compared
to baseline (all Bonferroni corrected P< .008) with the exception of
TAPSE_N. Figure 1 allows visualization of the response of individual
dogs, and it should be noted that not all dogs’ indices of systolic func-
tion were decreased post-sotalol. For example, 5 dogs had a measured
increase in LV EF post-sotalol (Figure 1D). Additionally, sinus heart
rate, number of VPCs/5 min, and arrhythmia grade all were significantly
(all P .014) decreased post-sotalol. At their baseline assessment, 9
dogs (33%) in the sotalol group had LV systolic dysfunction. Seven
dogs (26%) had RV systolic dysfunction, 3 of which also had LV systolic
dysfunction. Eight dogs (30%) had LA enlargement, 5 of which also had
LV systolic dysfunction. None of the dogs experienced any adverse
events including respiratory difficulty, syncope, collapse, lethargy, or
weakness after the single dose of sotalol.
Eight dogs were enrolled in the control group, and a summary of
their electrocardiographic and echocardiographic data is presented in
Table 2. Mean (SD) age was 10.4 (1.9) years. Body weight was 29.7
(10.1) kg. Three dogs (38%) were female. The control group consisted
of 2 Labrador Retrievers, a Weimaraner, Bull Terrier, mixed breed dog,
Bulldog, and a Boxer. Echocardiographic diagnoses of dogs in the con-
trol group included the following: echocardiographically unremarkable
in 3 dogs, myxomatous mitral valve disease and a heart base mass in 2
dogs each, and DCM in 1 dog. Two dogs (25%) in the control group
were diagnosed with LV systolic dysfunction and 1 dog (13%) was diag-
nosed with RV systolic dysfunction. Two dogs (25%) had LA
enlargement. No statistically significant differences were identified
between the control and sotalol group for body weight (P5 .61), age
(P5 .42), proportion of female dogs (P5 .10), sinus heart rate (P5 .51),
number of VPCs/5 min (P5 .72), arrhythmia grade (P5 .24), proportion
of dogs with LV systolic dysfunction (P5 .66), proportion of dogs with
RV systolic dysfunction (P5 .44), and proportion of dogs with LA
enlargement (P5 .80).
Percent change in ventricular function indices in the control versus
sotalol groups are presented in Figure 2. Percent change of LV FS (–
13.5 [11.3]%), LV SA (–9.6 [12.0]%), TAPSE_N (–4.9 [14.5]%), and RV
S’ (–18.8 [23.9]%) post-sotalol were not significantly different (all
P .06) when compared with the percent change of controls (–4.3
[15.6]%, 0.6 [12.3]%, 29.4 [17.9]%, 29.9 [20.9]%, respectively). How-
ever, percent change of LVIDs_N (11.0 [10.0]%) and LV EF post-sotalol
(–11.7 [15.6]%) were significantly different (P .0079) compared with
the percent change of the same indices in control dogs (2.1 [4.8]%, 0.4
[8.0]%, respectively).
Coefficients of variation for within-day variability of the echocar-
diographic indices of ventricular systolic function were as follows:
LVIDs_N52.7%, LV FS58.6%, LV SA55.5%, LV EF54.2%,
TAPSE_N512.5%, and RV S’516.6%.
4 | DISCUSSION
Results of our study show that, with the exception of TAPSE_N, all
studied echocardiographic indices of RV and LV systolic function eval-
uated after a single PO dose of sotalol were mildly decreased in dogs
with ventricular arrhythmias when compared with baseline. To help
delineate the clinical relevance of these changes, the percent change of
each ventricular systolic function index post-sotalol was compared to
the percent change of controls that underwent the same study proto-
col but were not treated with sotalol (to rule out an effect of within-
day variability or acclimation). Only the percent change in LVIDs_N and
LV EF post-sotalol were found to demonstrate a mild but significant
TABLE 1 Electrocardiographic and echocardiographic ventricular function data of dogs (n527) at baseline and post-sotalol
Baseline Postsotalol
Percent
change (%)
P-value (baseline
vs. post-sotalol)
Electrocardiographic variables
Sinus heart rate (min21) 120 (29) 97 (22) 217.6 (14.7) <.0001
VPCs/5-mina 18 (9–32) 4 (0–17) – <.0001
Arrhythmia severity gradea 1 (1–4) 1 (0–1) – .014
Echocardiographic variables
LVIDs_N 1.0 (0.17) 1.1 (0.17) 11.0 (10.0) <.0001
LV FS (%) 29.2 (6.0) 24.7 (6.2) 213.5 (11.3) <.0001
LV SA (%) 44.7 (12.0) 40 (11.5) 29.6 (12.0) .0002
LV EF (%) 50.3 (10.9) 43.3 (9.1) 211.7 (15.6) .0005
TAPSE_N 0.54 (0.13) 0.51 (0.11) 24.9 (14.5) .041
RV S’ (cm/s) 16.8 (5.8) 12.7 (3.0) 218.8 (23.9) .0007
Normally distributed data presented as mean (SD).
aNon-normally distributed data presented as median (interquartile range).
Abbreviations: LVIDs_N, left ventricular internal dimension at end-systole normalized to bodyweight; LV EF, left ventricular ejection fraction; LV FS,
left ventricular shortening fraction; LV SA, left ventricular shortening area; RV S’, peak systolic RV myocardial velocity at the lateral tricuspid annu-
lus; TAPSE_N, tricuspid annular plane systolic excursion normalized to bodyweight; VPC, ventricular premature complex.
Bolded P-values denote statistical significance (Bonferroni corrected P< .008).
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FIGURE 1 Left ventricular internal dimension at end-systole normalized to bodyweight (LVIDs_N) (A), Left ventricular fractional shortening
(LV FS) (B), left ventricular shortening area (LV SA) (C), left ventricular ejection fraction (LV EF) (D), TAPSE normalized to bodyweight (TAP-
SE_N) (E), and peak systolic RV myocardial velocity at the lateral tricuspid annulus (RV S’) (F) from 27 dogs at baseline and 2–4 hours post-
sotalol 2-2.5 mg/kg PO. Statistical significance was reached for all presotalol and post-sotalol comparisons (Bonferroni corrected P< .008)
with the exception of TAPSE_N
TABLE 2 Electrocardiographic and echocardiographic ventricular function data at baseline (exam 1) and 2–4 hours later (exam 2) of control
dogs (n58)
Exam 1 Exam 2 Percent change (%) P-value (Exam 1 vs. exam 2)
Electrocardiographic variables
Sinus heart rate (min21) 112 (22) 114 (23) 217.6 (14.7) .61
VPCs/5-mina 14.5 (6–39) 17.5 (4.75-24.3) – .46
Arrhythmia severity gradea 1 (0.25-2) 1 (0–1.75) – .38
Echocardiographic variables
LVIDs_N 1.0 (0.21) 1.0 (0.19) 2.1 (4.8) .34
LV FS (%) 29.9 (9.8) 28.9 (8.8) 24.3 (16) .59
LV SA (%) 52.8 (9.4) 53.8 (11.2) 0.6 (12.3) .66
LV EF (%) 55.4 (10.0) 55.9 (10.7) 0.4 (7.9) .70
TAPSE_N 0.54 (0.06) 0.49 (0.12) 29.4 (17.9) .20
RV S’ (cm/s) 15.5 (4.6) 13.5 (3.1) 29.9 (20.9) .11
Normally distributed data presented as mean (SD).
aNon-normally distributed data presented as median (interquartile range).
Abbreviations: LVIDs_N, left ventricular internal dimension at end-systole normalized to bodyweight; LV EF, left ventricular ejection fraction; LV FS,
left ventricular shortening fraction; LV SA, left ventricular shortening area; RV S’, peak systolic RV myocardial velocity at the lateral tricuspid annu-
lus; TAPSE_N, tricuspid annular plane systolic excursion normalized to bodyweight; VPC, ventricular premature complex.
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decrease in LV systolic function compared to the percent change of
controls whereas the other 4 indices (2 of LV systolic function and 2 of
RV systolic function) were not significantly different from controls.
These findings suggest the documented changes in LVIDs_N and LV EF
were likely caused by sotalol and not secondary to variability of the
echocardiographic indices or acclimation to the hospital environment,
as may be the case for the other studied indices of systolic function
(LV FS, LV SA, TAPSE_N, and RV S’). Clinically, the single dose of sota-
lol was well tolerated, even in dogs with systolic dysfunction or left
atrial enlargement, and no adverse effects occurred during the monitor-
ing period.
Our study was designed to determine the acute echocardiographic
effects of sotalol on RV and LV systolic function in a clinically relevant
manner. The results should be considered to provide pharmacodynam-
ics data and not as a therapeutic trial. Previous studies in dogs4,5 evalu-
ating the inotropic effect of sotalol have used a more precise method
of evaluating systolic function, LV 1dP/dt, under experimental condi-
tions in a more controlled and invasive manner while the dogs were
under general anesthesia. These studies found that sotalol at a dose of
2 mg/kg did not significantly decrease LV systolic function compared
to baseline. Unlike the pure b–blocker esmolol, sotalol attenuated the
decrease in systolic function noted with esmolol.4 Our study found
that 2 systolic function indices (LVIDs_N and LV EF) indicated a mild
decrease in LV systolic function post-sotalol beyond within-day vari-
ability controls. Differences in study design (anesthetized healthy dogs
versus awake dogs with ventricular arrhythmias) and methods of quan-
tifying systolic function (use of an invasive gold standard versus echo-
cardiography) are important considerations when comparing studies.
Despite the advantage of more accurately quantifying systolic function,
these studies were performed in a smaller number of healthy anesthe-
tized dogs. By not studying this effect in awake dogs with ventricular
arrhythmias (ie, the most likely patient population to be managed with
sotalol), the general clinical extrapolation of their results is limited. In
addition, the b–blocker effects and thus inotropic effects of sotalol
likely will have different effects in awake versus anesthetized dogs,
because awake dogs likely have higher sympathetic tone susceptible to
b–blockade. Lastly, differences in drug formulation also potentially
could help explain how our results differed. Because of the unavailabil-
ity of sotalol for parenteral use in the United States, we evaluated the
more clinically relevant effects of PO sotalol (versus IV) on systolic
function.
Four of 6 echocardiographic indices of systolic function failed to
show a statistically significant difference in percent change post-sotalol
compared with percent change of controls. The percent change post-
sotalol for LVIDs_N and LV EF identified were considered mild with an
11%-12% changed noted. A likely explanation for the significant
FIGURE 2 Scatter dot plots of LV internal dimension at end-systole normalized to bodyweight (LVIDs_N) (A), left ventricular fractional
shortening (LV FS) (B), left ventricular shortening area (LV SA) (C), left ventricular ejection fraction (LV EF) (D), TAPSE normalized to body-
weight (TAPSE_N) (E), and peak systolic RV myocardial velocity at the lateral tricuspid annulus (RV S’) (F) comparing the percent change in
ventricular function of dogs in the control group (n58) verses dogs that received sotalol (n527). For each group, horizontal lines and error
bars represent mean and SD. Statistically significant differences (Bonferroni corrected P< .008) were identified when comparing the percent
change of LVIDs_N (P5 .002) and LV EF (P5 .0079) post-sotalol to the percent change of the same indices in control dogs. Statistically sig-
nificant differences were not identified for the other indices of ventricular systolic function
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difference between LVIDs_N and LV EF and their respective controls
might be because these indices were found to have the lowest within-
day variability coefficients of variation (LVIDs_N52.7% and LV
EF54.2%) compared with the other indices and are therefore more
sensitive at detecting smaller changes beyond within-day variability. It
is also possible LVIDs_N and LV EF are more accurate indices of sys-
tolic function, but this was not assessed in our study.
In humans, considerable clinical evidence documents PO sotalol’s
lack of effect on systolic function (LV EF determined by radionuclide
angiography) in the majority of cases.24–27 However, most of these
studies evaluated LV EF after more long-term treatment, which could
explain the differences in our findings. Interestingly, one of the previ-
ously mentioned invasive studies in dogs5 noted a similar significant
decrease in systolic function (LV 1dP/dt) after the 1st dose of sotalol
when compared with baseline. After repeated dosing, however, systolic
function increased and was not significantly different from baseline.
The authors attributed this initial effect to sotalol’s b–blocking proper-
ties and the later increase in systolic function to an increase in intracel-
lular calcium concentration.5 Given these findings and the results of
our study, dose titration of sotalol may be ideal, particularly in dogs
with decreased systolic function, as has been advocated by some.28
Several of the dogs in our study were diagnosed with systolic dys-
function, including 9 (33%) with LV systolic dysfunction (5 of which
had LA enlargement), 7 (26%) with RV systolic dysfunction, and 3
(11%) with both. None of the dogs in our study experienced any
adverse effects, including overt signs of low cardiac output or conges-
tion, secondary to sotalol administration during the monitoring period.
However, the short-term nature of our study design and lack of objec-
tive monitoring criteria (eg, heart rate with continuous ECG, respiratory
rate, blood pressure) should be emphasized, and these results should
be interpreted with caution. One study evaluating sotalol’s antiarrhyth-
mic effect in Boxers with ventricular arrhythmias showed that sotalol
was well tolerated when administered for 21–28 days.2 However,
results of systolic function assessment were not reported.
Our study showed that a single PO dose of sotalol significantly
decreases sinus heart rate, number of VPCs/5-minutes, and arrhythmia
severity grade 2–4 hours post-sotalol as assessed by a 5-minutes ECG.
A proarrhythmic effect of sotalol was not identified by the 5-minutes
ECG post-sotalol. These results agree with a study2 evaluating the
more long-term antiarrhythmic effects of sotalol in Boxers with ventric-
ular arrhythmias using 24-hours Holter monitor analysis in which a lack
of a proarrhythmic effect and decreases in average heart rate, VPCs/24
hours, and arrhythmia grade also were documented. However, because
of the relative insensitivity of 5-minutes ECGs,29 a more robust ECG
assessment (ie, 24-hours ambulatory ECG) is necessary to confirm our
findings and more accurately judge the effectiveness of sotalol on ven-
tricular ectopy in our patient population.
Our study had several limitations, including the relatively few num-
ber of dogs in our control group, a lack of a gold standard to assess sys-
tolic function (also discussed above) and the short-term nature of our
study design based on a single PO dose of sotalol. In addition, the dogs
that made up our study sample were affected by a variety of diseases
(known or unknown) associated with ventricular arrhythmias. This
represents a limitation of our study design insomuch as our results can-
not be directly translated to a single disease entity such as preclinical
DCM of the Doberman pinscher. Our findings cannot necessarily be
extrapolated to dogs being treated with sotalol chronically or when the
drug has reached steady state. Our study design mandated that the
post-sotalol evaluations were performed during a narrow range of time
(2–4 hours postpill). Drug concentrations of sotalol were not measured
to evaluate differences in drug absorption or patient metabolism. In
addition, we did not determine if the dogs in our study were affected
by a b–adrenergic receptor polymorphism.30 These polymorphisms
have been shown to impact heart rate response to atenolol in healthy
dogs, and, as such, their possible role in our patient population is
unknown.31 These limitations are certainly potential explanations for
the variability of an individual dog’s response to sotalol depicted for
each of the echocardiographic indices in Figure 1. We were unable to
identify common characteristics such as breed or type or severity of
structural cardiac disease in the minority of dogs that did not show a
mild decrease in systolic function post-sotalol (ie, the 5 dogs in which
LV EF increased post-sotalol). Other potential explanations for the indi-
vidual variability noted for both control dogs and dogs that received
sotalol would be flaws or lack of precision or accuracy in the echocar-
diographic indices used, measurement variability, or the occurrence of
human error on some of the measurements. Demonstration of drug
absorption coupled with evaluation of systolic function by a gold stand-
ard index would have been ideal to document the true pharmacologic
response or lack thereof in each dog. We also did not monitor the
dogs’ cardiac rhythm throughout the study period and consider the 5-
minutes ECG assessment (versus more prolonged or thorough ECG
monitoring) a limitation of our study. For example, frequent ventricular
ectopy before the post-sotalol echocardiographic examination could
have been a primary reason for decreased systolic function (because of
myocardial stunning) noted in some dogs. Lastly, we acknowledge that
having multiple sonographers with varying levels of experience perform
the echocardiographic examinations represents a limitation. It would
have been ideal for all of the echocardiographic studies to have been
performed by the same sonographer. However, doing so often is
impractical. In our opinion, the most important comparison in our study
is the change noted within each individual dog, and the same sonogra-
pher performed repeat echocardiographic examinations in most of the
cases (in all but 3 dogs). Despite these limitations, our study results pro-
vide clinicians with valuable information on the acute echocardio-
graphic effects of sotalol on ventricular function in dogs with
ventricular arrhythmias.
In conclusion, our study shows that a single PO dose of sotalol
may cause a mild decrease in LV systolic function in dogs with ventric-
ular arrhythmias when assessed by LVIDs_N and LV EF. Significant dif-
ferences beyond the percent change of control dogs were not
documented when assessed by 4 other echocardiographic indices of
ventricular systolic function (LV FS, LV SA, TAPSE_N, and RV S’).
Despite the possibility of a mild decrease in ventricular systolic func-
tion, a single PO dose of sotalol appears to be well tolerated, even in
dogs with left atrial enlargement or systolic dysfunction because no
adverse effects were noted during the study period. Additional longer-
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term studies with a larger number of controls would be ideal to confirm
our findings.
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